BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

838 related articles for article (PubMed ID: 21538327)

  • 21. Pulmonary arterial hypertension and systemic sclerosis relation: a single centre experience.
    Demir N; Şahin A; Küçükşahin O; Kayacan O; Dinçer İ; Sayın T; Karnak D; Turgay M
    Heart Lung Circ; 2014 Jul; 23(7):667-73. PubMed ID: 24613044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Six-minute walk test in systemic sclerosis: A systematic review and meta-analysis.
    Vandecasteele E; De Pauw M; De Keyser F; Decuman S; Deschepper E; Piette Y; Brusselle G; Smith V
    Int J Cardiol; 2016 Jun; 212():265-73. PubMed ID: 27057932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.
    Yuan YP; Yuan P; Su YL; Jiang R; Zhang R; He J; Qiu HL; Luo CJ; Liu JM; Gong SG; Wang L; Zhao QH
    Clin Rheumatol; 2022 Jun; 41(6):1675-1686. PubMed ID: 35099674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
    Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A
    Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).
    Benza RL; Miller DP; Gomberg-Maitland M; Frantz RP; Foreman AJ; Coffey CS; Frost A; Barst RJ; Badesch DB; Elliott CG; Liou TG; McGoon MD
    Circulation; 2010 Jul; 122(2):164-72. PubMed ID: 20585012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies.
    Le Pavec J; Lorillon G; Jaïs X; Tcherakian C; Feuillet S; Dorfmüller P; Simonneau G; Humbert M; Tazi A
    Chest; 2012 Nov; 142(5):1150-1157. PubMed ID: 22459770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up.
    Vilela VS; Dias MM; Salgado ÂA; da Silva BRA; Lopes AJ; Bessa EJC; Bruno LP; da Costa CH; Levy RA; Rufino R
    BMC Pulm Med; 2021 Jul; 21(1):251. PubMed ID: 34325685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH.
    Clements PJ; Tan M; McLaughlin VV; Oudiz RJ; Tapson VF; Channick RN; Rubin LJ; Langer A;
    Ann Rheum Dis; 2012 Feb; 71(2):249-52. PubMed ID: 21998119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Lung involvement in systemic sclerosis].
    Posa M; Stelle M; Lador F; Chizzolini C
    Rev Med Suisse; 2015 Apr; 11(469):802-6. PubMed ID: 26040160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
    Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
    Furuya Y; Kuwana M
    J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment.
    Proudman SM; Stevens WM; Sahhar J; Celermajer D
    Intern Med J; 2007 Jul; 37(7):485-94. PubMed ID: 17547726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters.
    Fischer A; Swigris JJ; Bolster MB; Chung L; Csuka ME; Domsic R; Frech T; Hinchcliff M; Hsu V; Hummers LK; Gomberg-Maitland M; Mathai SC; Simms R; Steen VD
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-109-14. PubMed ID: 25372796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression.
    Goh NS; Veeraraghavan S; Desai SR; Cramer D; Hansell DM; Denton CP; Black CM; du Bois RM; Wells AU
    Arthritis Rheum; 2007 Jun; 56(6):2005-12. PubMed ID: 17530640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement.
    Fischer A; Kong AM; Swigris JJ; Cole AL; Raimundo K
    J Rheumatol; 2018 Feb; 45(2):235-241. PubMed ID: 29142033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Esophageal involvement and pulmonary manifestations in systemic sclerosis.
    Marie I; Dominique S; Levesque H; Ducrotté P; Denis P; Hellot MF; Courtois H
    Arthritis Rheum; 2001 Aug; 45(4):346-54. PubMed ID: 11501722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bosentan in pulmonary arterial hypertension secondary to scleroderma.
    Joglekar A; Tsai FS; McCloskey DA; Wilson JE; Seibold JR; Riley DJ
    J Rheumatol; 2006 Jan; 33(1):61-8. PubMed ID: 16395751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determinants of pulmonary arterial hypertension in scleroderma.
    Plastiras SC; Karadimitrakis SP; Kampolis C; Moutsopoulos HM; Tzelepis GE
    Semin Arthritis Rheum; 2007 Jun; 36(6):392-6. PubMed ID: 17204309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulmonary hypertension in interstitial lung disease: prevalence, prognosis and 6 min walk test.
    Andersen CU; Mellemkjær S; Hilberg O; Nielsen-Kudsk JE; Simonsen U; Bendstrup E
    Respir Med; 2012 Jun; 106(6):875-82. PubMed ID: 22425136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nailfold capillary density is associated with the presence and severity of pulmonary arterial hypertension in systemic sclerosis.
    Hofstee HM; Vonk Noordegraaf A; Voskuyl AE; Dijkmans BA; Postmus PE; Smulders YM; Serné EH
    Ann Rheum Dis; 2009 Feb; 68(2):191-5. PubMed ID: 18375538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.